----item----
version: 1
id: {159ADCBD-94A4-40E2-B290-E149B98582D9}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/02/02/Valeant ups bid for Dendreons Provenge to 400m
parent: {DC974173-C28C-42F8-B0EA-A3ED5BCCC587}
name: Valeant ups bid for Dendreons Provenge to 400m
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 1b5563fc-82c5-4f89-9437-3463f5e59b65

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 48

Valeant ups bid for Dendreon's Provenge to $400m
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 46

Valeant ups bid for Dendreons Provenge to 400m
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1542

<p>Valeant Pharmaceuticals has increased its bid by more than $100m to acquire the personalized prostate cancer immunotherapy Provenge (sipuleucel-T) and other Dendreon assets for $400m.</p><p>With $620m in debt on its balance sheet and only $100m in cash, Seattle, Washington-based Dendreon filed for Chapter 11 bankruptcy protection in November, so its sale for at least $275m &ndash; an amount agreed upon by the company's creditors &ndash; must be approved by the bankruptcy court (scripintelligence.com, <a href="http://www.scripintelligence.com/home/Dendreon-seeks-Chapter-11-bankruptcy-as-620m-debt-looms-354946" target="_new">10 November 2014</a>). </p><p>Valeant's original $296m offer recently was selected as the "stalking horse" bid, which is the starting point for other potential buyers (scripintelligence.com, <a href="http://www.scripintelligence.com/home/Valeant-bids-296m-for-Dendreon-assets-356469" target="_new">30 January 2015</a>).</p><p>Quebec, Canada-based Valeant's revised bid sets a new high bar for the ongoing auction of Dendreon's assets, which include the $300m-per-year prostate cancer treatment Provenge and related manufacturing facilities. The bid submission deadline is 5 p.m. Eastern on 10 February and the auction will take place on 12 February.</p><p>In the interim, Dendreon continues to manufacture and sell Provenge.</p><p>The company's stock closed 20.9% higher at $0.18 per share on 5 February following the announcement of Valeant's increased bid. Dendreon's market cap is $29m.</p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 190

<p>Valeant Pharmaceuticals has increased its bid by more than $100m to acquire the personalized prostate cancer immunotherapy Provenge (sipuleucel-T) and other Dendreon assets for $400m.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 46

Valeant ups bid for Dendreons Provenge to 400m
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150202T080002
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150202T080002
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150202T080002
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027741
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 48

Valeant ups bid for Dendreon's Provenge to $400m
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356487
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042247Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

1b5563fc-82c5-4f89-9437-3463f5e59b65
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042247Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
